58 research outputs found

    InfluĂȘncia das condiçÔes do habitat sobre a estrutura de herbĂĄceas aquĂĄticas na regiĂŁo do Lago CatalĂŁo, Manaus, AM

    Get PDF
    Na AmazĂŽnia, as herbĂĄceas aquĂĄticas sĂŁo encontradas em todas as tipologias de ĂĄgua, mas sua abundĂąncia pode ser influenciada pelas condiçÔes limnolĂłgicas de cada ambiente. Assim, este trabalho teve como objetivo avaliar a influĂȘncia das condiçÔes do habitat sobre a estrutura de herbĂĄceas aquĂĄticas na regiĂŁo do Lago CatalĂŁo, Manaus, AM. Foram avaliadas sete transecçÔes em ambientes de ĂĄgua branca (AB), nove em ĂĄgua decantada (AD) e sete em ĂĄgua mista (AM). Em cada transecção foram identificadas as herbĂĄceas aquĂĄticas, estimada a ĂĄrea de cobertura relativa, calculada a frequĂȘncia de ocorrĂȘncia e avaliadas as variĂĄveis turbidez, condutividade elĂ©trica, pH e profundidade. A variação na profundidade indicou que os ambientes de AD e AM eram mais profundos do que AB, jĂĄ ĂĄguas mais ĂĄcidas e com menor condutividade foram registradas na AM. Foram registrados 32 tĂĄxons de herbĂĄceas aquĂĄticas sendo as espĂ©cies mais frequentes Paspalum repens, Salvinia auriculata, Pistia stratiotes e Lemna valdiviana. Entre as espĂ©cies levantadas, 50% foram comuns aos trĂȘs ambientes. Por outro lado, algumas espĂ©cies ocorreram exclusivamente em ambientes de AB, em AD e em AM. Na AB foram mais frequentes as formas flutuantes, que tambĂ©m apresentaram a maior cobertura neste ambiente; na AD e na AM as emersas apresentaram maior frequĂȘncia e cobertura. A AM apresentou maior riqueza de herbĂĄceas aquĂĄticas em relação aos demais ambientes. As variaçÔes registradas indicam que as condiçÔes limnolĂłgicas dos rios de ĂĄgua branca e preta podem determinar a estrutura da comunidade de herbĂĄceas aquĂĄticas, mesmo em pequenas escalas espaciais

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362
    • 

    corecore